Unicycive Therapeutics, Inc. (UNCY)
NASDAQ: UNCY · Real-Time Price · USD
0.508
-0.001 (-0.26%)
Nov 21, 2024, 12:53 PM EST - Market open
Unicycive Therapeutics Employees
Unicycive Therapeutics had 14 employees as of December 31, 2023. The number of employees increased by 2 or 16.67% compared to the previous year.
Employees
14
Change (1Y)
2
Growth (1Y)
16.67%
Revenue / Employee
n/a
Profits / Employee
-$1,721,214
Market Cap
52.74M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 14 | 2 | 16.67% |
Dec 31, 2022 | 12 | 3 | 33.33% |
Dec 31, 2021 | 9 | 8 | 800.00% |
Dec 31, 2020 | 1 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Burning Rock Biotech | 786 |
LakeShore Biopharma | 758 |
BGM Group | 298 |
Apyx Medical | 252 |
Affimed | 76 |
CollPlant Biotechnologies | 75 |
HCW Biologics | 45 |
Protara Therapeutics | 27 |
UNCY News
- 6 hours ago - Unicycive Therapeutics to Participate in Two Upcoming Investor Conferences Including a Fireside Chat at the Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 8 days ago - Unicycive Announces Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 10 days ago - Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis - GlobeNewsWire
- 24 days ago - Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024 - GlobeNewsWire
- 5 weeks ago - Unicycive Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit on October 17, 2024 - GlobeNewsWire
- 5 weeks ago - Unicycive Therapeutics Announces Late-Breaker Poster Presentation on Oxylanthanum Carbonate (OLC) at the American Society of Nephrology (ASN) Kidney Week 2024 - GlobeNewsWire
- 6 weeks ago - Unicycive Therapeutics Successfully Completes UNI-494 Phase 1 Study in Healthy Volunteers - GlobeNewsWire
- 2 months ago - Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024 - GlobeNewsWire